Press release
Treatment-resistant Hypertension Market Size in the 7MM was over USD 13 billion in 2021
The Treatment-resistant Hypertension market report provides current treatment practices, Treatment-resistant Hypertension emerging drugs, and Treatment-resistant Hypertension market share of the individual therapies, current and forecasted Treatment-resistant Hypertension symptoms market size from 2019 to 2032 segmented by 7MM. The report also covers current Treatment-resistant Hypertension symptoms, treatment practice/algorithm, and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the Treatment-resistant Hypertension market.
Key takeaways from the Treatment-resistant Hypertension Market Research Report
• The increase in Treatment-resistant Hypertension market size is a direct consequence of expected approval of emerging therapy and increasing patient population of Treatment-resistant Hypertension in the countries.
• As per the estimates, the United States has the largest prevalent population of Treatment-resistant Hypertension
• Among the EU5 countries, Germany had the highest prevalent cases of Treatment-resistant Hypertension, followed by Italy and Spain. On the other hand, the UK had the lowest prevalent cases, with ~600k cases in 2021.
• The leading Treatment-resistant Hypertension Market Companies includes Idorsia Ltd, Janssen Biotech, Quantum Genomics SA, CinCor Pharma, Ionis Pharmaceuticals, Vifor Pharma, KBP Biosciences, and others.
• Promising Treatment-resistant Hypertension Pipeline Therapies includes CIN-107, Firibastat, ROX COUPLER, and others.
Discover which therapies are expected to grab the major Treatment-resistant Hypertension market share, click here for Treatment-resistant Hypertension Market Research Report @ https://www.delveinsight.com/sample-request/treatment-resistant-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Treatment-resistant Hypertension Overview
Treatment-resistant Hypertension (Treatment-resistant Hypertension) is defined as uncontrolled blood pressure despite the use of ≥3 antihypertensive agents of different classes, including a diuretic, usually thiazide-like, a long-acting calcium channel blocker, or a blocker of the renin-angiotensin system, either an ACE (angiotensin-converting enzyme) inhibitor or an ARB (angiotensin receptor blocker), at maximal or maximally tolerated doses.
Treatment-resistant Hypertension Epidemiology Segmentation in the 7MM
• Total Treatment-resistant Hypertension Prevalent Cases
• Treatment-resistant Hypertension Gender-specific Cases
• Treatment-resistant Hypertension Age-specific Cases
Download the report to understand which factors are driving Treatment-resistant Hypertension market trends, click here for Treatment-resistant Hypertension Market Forecast @ https://www.delveinsight.com/sample-request/treatment-resistant-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Treatment-resistant Hypertension Emerging Drugs Profile
Aprocitentan: Idorsia Ltd/Janssen Biotech
Aprocitentan is an investigational, orally active dual endothelin receptor antagonist in development for the Treatment-resistant Hypertension (individuals with uncontrolled hypertension despite the use of at least three antihypertensive drugs).
Firibastat (QGC001): Quantum Genomics SA
The firibastat (originally named QGC001) product is a prodrug that delivers in the brain the EC33 product, a selective and specific inhibitor of Aminopeptidase A, thus preventing the production of Angiotensin III in the brain. Due to its unique action mechanism, firibastat represents an alternative therapeutic approach that can interfere with the mechanism involved in the genesis and control of blood pressure in hypertensive patients, especially those with a particular hormonal profile, characterized by a low renin concentration and a high vasopressin concentration (Low Renin High Vasopressin (LRHV) profile). Firibastat and its therapeutic use are strongly protected by several families of patents ensuring industrial protection until 2033 without considering the potential additional protection certificates.
CIN-107: CinCor Pharma
CIN-107 is a highly selective aldosterone synthase inhibitor being developed for large unmet medical needs, including resistant hypertension and primary aldosteronism. CIN-107 works through the renin-angiotensin-aldosterone system (RAAS), which regulates the body's fluid and electrolyte balance.
Treatment-resistant Hypertension Market Outlook
The report's Treatment-resistant Hypertension market outlook helps understand the historic, current better, and forecasted Treatment-resistant Hypertension market trends by analyzing the impact of current therapies on the market, unmet needs, SWOT analysis, and demand for better technology. At present, the therapeutic market size of Treatment-resistant Hypertension is mainly comprised of pharmacological therapies and non-pharmacological therapies. Non pharmacological interventions include lifestyle modifications, a DASH diet, reduced salt intake, restricted alcohol consumption, etc. Pharmacological interventions include withdrawal of interfering medication, optimization of three-drug regimen and diuretic therapy, combination therapy, and addition of mineralocorticoid receptor antagonists (spironolactone) as the fourth agent for treating Treatment-resistant Hypertension. According to DelveInsight, the Treatment-resistant Hypertension market in 7MM is expected to grow steadily during the study period 2019-2032.
Learn more about the Treatment-resistant Hypertension FDA-approved drugs, click here for Treatment-resistant Hypertension Emerging Drugs & Companies and Treatment-resistant Hypertension Treatment Market @ https://www.delveinsight.com/sample-request/treatment-resistant-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Treatment-resistant Hypertension Market Research Report
• Coverage- 7MM
• Treatment-resistant Hypertension Companies- Idorsia Ltd, Janssen Biotech, Quantum Genomics SA, CinCor Pharma, Ionis Pharmaceuticals, Vifor Pharma, KBP Biosciences, and others.
• Treatment-resistant Hypertension Pipeline Therapies- CIN-107, Firibastat, ROX COUPLER, and others.
• Treatment-resistant Hypertension Market Dynamics: Treatment-resistant Hypertension Market Barriers and Drivers
• Treatment-resistant Hypertension Market Access and Reimbursement
To discover more about Treatment-resistant Hypertension Market Drugs in development, click here for Treatment-resistant Hypertension Market Dynamics and Treatment-resistant Hypertension Market Drivers & Barriers @ https://www.delveinsight.com/sample-request/treatment-resistant-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Key Insights
2. Report Introduction
3. Treatment-resistant Hypertension (RHTN) Market Overview at a Glance
4. Executive Summary of Treatment-resistant Hypertension
5. Disease Background and Overview
6. Treatment-resistant Hypertension Epidemiology and Patient Population
7. Patient Journey
8. Treatment-resistant Hypertension Emerging Therapies
9. Other Promising Therapies
10. Treatment-resistant Hypertension (RHTN): 7 Major Market Analysis
11. SWOT Analysis
12. Treatment-resistant Hypertension Unmet Needs
13. KOL Views
14. Appendix
15. DelveInsight Capabilities
16. Disclaimer
17. About DelveInsight
To read more about the Treatment-Resistant Hypertension Patient Population of the report, click here for Treatment-Resistant Hypertension Unmet Needs and Patient Journey @ https://www.delveinsight.com/sample-request/treatment-resistant-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Treatment-resistant Hypertension Market Size in the 7MM was over USD 13 billion in 2021 here
News-ID: 2920256 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Treatment
Trigeminal Neuralgia Treatment Market Size, Trigeminal Neuralgia Treatment Marke …
Trigeminal Neuralgia Treatment Market Dynamics are clarified by an in-depth review of facts on current and emerging trends. To understand a resource, the paper uses Porter's five forces to examine the importance of numerous qualities such as understanding of suppliers and customers, dangers provided by various agents, competitive strength, and promising new businesses. precious. Furthermore, the study covers numerous firms' Trigeminal Neuralgia Treatment research data, benefit, gross margin, worldwide market…
Medical Tourism Market Report by Treatment Type (Dental Treatment, Cosmetic Trea …
The global medical tourism market accounted for $104.68 billion in 2019, and is projected to reach $273.72 billion by 2027, registering a CAGR of 12.8% from 2019 to 2027 in terms of value.
View Full Report: https://reports.valuates.com/market-reports/ALLI-Auto-0P310/medical-tourism
In terms of volume, the global medical tourism market accounted for 23,042.90 thousand patients in 2019, and is projected to reach 70,358.61 thousand patients by 2027, registering a CAGR of 15.0% from 2019 to…
Stretch Marks Treatment Market by Treatment & Forecast - 2025
Global Stretch Marks Treatment Market: Snapshot
In order to expand their outreach and add to their product portfolio, keen players in the global stretch marks treatment market are taking the inorganic route of acquisitions. They are also pouring money into development of new and better products.
Rising instances of obesity causing stretch marks is serving to catalyze growth in the market. In addition, growing aesthetic consciousness among people, especially among pregnant women,…
Stretch Marks Treatment Market by Treatment & Forecast - 2025
Global Stretch Marks Treatment Market: Snapshot
In order to expand their outreach and add to their product portfolio, keen players in the global stretch marks treatment market are taking the inorganic route of acquisitions. They are also pouring money into development of new and better products.
Rising instances of obesity causing stretch marks is serving to catalyze growth in the market. In addition, growing aesthetic consciousness among people, especially among pregnant women,…
Medical Tourism Market by Treatment Type (Dental Treatment, Cosmetic Treatment, …
Medical Tourism Market Overview:
The global medical tourism market was valued at $53,768 million in 2017, and is estimated to reach at $143,461 million by 2025, registering a CAGR of 12.9% from 2018 to 2025.
Organized travel across international borders to avail medical treatment of some form, which may or may not be available in the travelers home country is defined as medical tourism. Medical tourists travel abroad for the maintenance, enhancement,…
Substance Use Disorder Treatment Market By Type (Alcohol abuse treatment, Nicoti …
According to World Health Organization (WHO), the leading cause of disability around the world is not a physical disease, but a serious mood disorder known as depression. Around 350 million people suffer from depression worldwide, and that only about 50% of these individuals will ever receive treatment. According to Anxiety and Depression Association of America, in the U.S., over 15 million adults experience an episode of clinical depression in any…
